Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc (INM) is a clinical-stage biopharmaceutical leader developing cannabinoid-based therapies for complex medical conditions. This dedicated news hub provides investors and industry observers with timely updates on INM's research milestones, regulatory developments, and strategic initiatives.
Access comprehensive coverage of the company's progress in neurodegenerative, ocular, and dermatological drug development. Our curated news collection features official press releases alongside verified third-party analysis, offering a complete picture of INM's pipeline advancements and intellectual property developments.
Key updates include clinical trial results, regulatory submissions, partnership announcements, and manufacturing innovations related to INM-755, INM-089, and other proprietary candidates. The resource emphasizes INM's unique approach combining cannabinoid pharmacology with advanced delivery systems to address unmet medical needs.
Bookmark this page for streamlined access to essential updates about INM's therapeutic pipeline, patent portfolio expansions, and scientific presentations. Stay informed about the company's progress in developing small molecule therapies through this centralized, regularly updated resource.
InMed Pharmaceuticals (NASDAQ: INM) released its financial results for Q3 fiscal 2024, ending March 31, 2024.
The company reported positive preclinical data for its Alzheimer's disease (INM-901) and dry AMD (INM-089) programs. InMed closed the quarter with $7.9 million in cash.
The BayMedica commercial business earned $3.3 million over nine months, an 83% increase from the previous year. Q3 revenues remained flat at $1.2 million, with BayMedica operating profitably.
The company recorded a net loss of $5.7 million for the quarter, down from $7.6 million the previous year. R&D and patents expenses dropped to $2.6 million from $3.1 million. Cash reserves should cover expenses into Q4 2024.
Notably, Alexandra Mancini, SVP Clinical & Regulatory Affairs, will retire effective June 30, 2024.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
